Fed. Circ. Won't Undo Amgen's Cancer Drug IP Win
The Federal Circuit on Monday turned down an Indian drugmaker's efforts to reverse a Delaware judge's ruling that could keep Amgen's grip on its anti-cancer drug Kyprolis firm for at least...To view the full article, register now.
Already a subscriber? Click here to view full article